Illumina Developing Avantome Sequencing for Clinical Applications | GenomeWeb

By Julia Karow

Illumina is developing its Avantome sequencing technology for clinical applications and eventually plans to obtain 510(k) clearance from the US Food and Drug Administration for the platform it plans to launch, according to the company's CEO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.